Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients

Journal of Hepatology

Volumn 60, Issue 4, 2014, Pages 715-722

  Berg, Thomas ^a   Zoulim, Fabien ^b   Moeller, Bernd ^c   Trinh, Huy ^d   Marcellin, Patrick ^e   Chan, Sing ^f   Kitrinos, Kathryn M ^g   Dinh, Phillip ^g   Flaherty, John F ^g   McHutchison, John G ^g   Manns, Michael ^h  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b HOSPICES CIVILS DE LYON   (France)

^c Private Practice   (Germany)

^d Private Practice   (United States)

^e BEAUJON HOSPITAL   (France)

^f Private Practice   (United States)

^g GILEAD SCIENCES   (United States)

^h HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Adefovir; Combination treatment; Emtricitabine; Hepatitis B; Monotherapy; Mutations; Resistance; Tenofovir

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; CREATININE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PHOSPHORUS; PLACEBO; TENOFOVIR DISOPROXIL; VIRUS DNA; ADEFOVIR; ADENINE; ANTIVIRUS AGENT; DEOXYCYTIDINE; EMTRICITABINE; HEPATITIS B ANTIBODY; PHOSPHONIC ACID DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BONE METASTASIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY FUNCTION; LONG TERM CARE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUTATION; OPEN STUDY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; BLOOD; DRUG COMBINATION; DRUG EFFECTS; HEPATITIS B, CHRONIC; IMMUNOLOGY; VIROLOGY;

ADENINE; ANTIVIRAL AGENTS; DEOXYCYTIDINE; DNA, VIRAL; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B, CHRONIC; HUMANS; MALE; ORGANOPHOSPHONATES; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 84896392012     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.11.024     Document Type: Article

References (26)

1. C.L. Lai, and M.F. Yuen Chronic hepatitis B - new goals, new treatment N Engl J Med 359 2008 2488 2491
2. P. Marcellin, E.J. Heathcote, M. Buti, E. Gane, R.A. de Man, and Z. Krastev et al. Tenofovir disoproxil fumarate vs. adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2008 2442 2455
3. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
4. Y.F. Liaw, N. Leung, J.H. Kao, T. Piratvisuth, E. Gane, and K.H. Han et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update Hepatol Int 2 2008 263 283
5. T.T. Chang, C.L. Lai, S. Kew Yoon, S.S. Lee, H.S. Coelho, and F.J. Carrilho et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B Hepatology 51 2010 422 430
6. J.G. Reijnders, and H.L. Janssen Potency of tenofovir in chronic hepatitis B: mono or combination therapy? J Hepatol 48 2008 383 386
7. D.J. Tenney, R.E. Rose, C.J. Baldick, K.A. Pokornowski, B.J. Eggers, and J. Fang et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy Hepatology 49 2009 1503 1514
8. J.W. Park, H.S. Kim, D.D. Seo, J.S. Jang, W.G. Shin, and K.H. Kim et al. Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance J Viral Hepat 18 2011 e475 e481
9. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
10. E.J. Heathcote, P. Marcellin, M. Buti, E. Gane, R.A. De Man, and Z. Krastev et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B Gastroenterology 140 2011 132 143
11. Marcellin P, Heathcote EJ, Corsa A, Liu Y. No detectable resistance to tenofovir disoproxil fumarate (TDF) following up to 240 weeks of treatment in patients with HBeAg+ and HBeAg- chronic hepatitis B virus infection. In: 62nd annual meeting of the American Association for the Study of Liver Diseases, November 4-8, San Francisco, CA; 2011.
12. A. Snow-Lampart, B. Chappell, M. Curtis, Y. Zhu, F. Myrick, and J. Schawalder et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus Hepatology 53 2011 763 773
13. G. Woo, G. Tomlinson, Y. Nishikawa, M. Kowgier, M. Sherman, and D.K. Wong et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses Gastroenterology 139 2010 1218 1229
14. S.K. Fung, T. Mazzulli, and M. Sherman Presence of rtA194T at baseline does not reduce efficacy to tenofovir (TDF) in patients with lamivudine (LAM)-resistant chronic hepatitis B Hepatology 48 2008 699A
15. Levrero M, Cimino L, Lampertico P. Tenofovir (TDF) for chronic hepatitis B patients with suboptimal response to adefovir (ADV) or ADV/LAM treatment: results of the OptiB Italian Multicenter Prospective Open Label Study. In: Annual meeting of the American Association for the Study of Liver Diseases, October 29-November 2, Boston, MA; 2010.
16. A. Ong, V.W. Wong, G.L. Wong, H.Y. Chan, C.H. Tse, and H.L. Chan Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir Aliment Pharmacol Ther 34 2011 972 981
17. S.J. Patterson, J. George, S.I. Strasser, A.U. Lee, W. Sievert, and A.J. Nicoll et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B Gut 60 2011 247 254
18. F. van Bömmel, R.A. de Man, H. Wedemeyer, K. Deterding, J. Petersen, and P. Buggisch et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues Hepatology 51 2010 73 80
19. T. Berg, P. Marcellin, F. Zoulim, B. Moller, H. Trinh, and S. Chan et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection Gastroenterology 139 2010 1207 1217
20. Y. Zhu, M. Curtis, and K. Borroto-Esoda HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A-H and its use in antiviral phenotyping assays J Virol Methods 173 2011 340 346
21. R.G. Gish, M.D. Clark, S.D. Kane, R.E. Shaw, M.F. Mangahas, and S. Baqai Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B Clin Gastroenterol Hepatol 10 2012 941 946
22. F. Wong, M.F. Nadim, J.A. Kellum, F. Salerno, R. Bellomo, and A. Gerbes et al. Working party proposal for a revised classification system of renal dysfunction in patients with cirrhosis Gut 60 2011 702 709
23. Lavocat F, Pichoud C, Deny P, Borroto-Esoda K, Sorbel J, Rousseau F, et al. Evolution of viral load and genome sequence in a clinical trial of tenofovir/emtricitabine combination vs. tenofovir monotherapy for patients with previous adefovir dipivoxil failure. In: Annual meeting of the European Association for the Study of the Liver, April 22-26; Copenhagen, Denmark; 2009.
24. E.S. Svarovskaia, M. Curtis, Y. Zhu, K. Borroto-Esoda, M.D. Miller, and T. Berg et al. Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen J Viral Hepat 20 2013 131 140
25. P. Marcellin, E. Gane, M. Buti, N. Afdhal, W. Sievert, and I. Jacobson et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow up study Lancet 381 2013 468 475
26. S.N. Si-Ahmed, P. Pradat, R. Zoutendijk, M. Buti, V. Mallet, and C. Cruiziat et al. Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study Antiviral Res 92 2011 90 95